Acute myeloid leukemia (AML) is a disease of older persons that has a dismal outcome and patients unfit for intensive chemotherapy exhibit a median survival of only 5 to 10 months . However, the therapeutic landscape of AML is changing with the appearance of new-targeted drugs such as BH3 mimetics that inhibit prosurvival BCL2 family […]
Acute myeloid leukemia (AML) is a major hematopoietic malignancy characterized by the uncontrolled expansion of the immature myeloid cells . The 5-year survival rates of young patients are 40–50% and less than 15% for patients aged over 60 . For this reason, a great effort has been made to decipher the molecular events underlying AML […]
Acute myeloid leukemia (AML) is a stem cell disease caused by the massive mobilization and differentiation arrest in primordial granulocytes. AML is characterized by a low survival rate and high recurrence . Although differentiation-induction therapy represents an innovative treatment strategy for AML , many problems still exist, including irreversible resistance, toxic effects, and limitations of […]
Acute Myeloid Leukemia (AML) is a hematopoietic neoplasm characterized by the proliferation and accumulation of aberrant immature myeloid progenitor cells. AML is associated with poor clinical outcome and high mortality, with an overall five-year survival rate of less than 15-30%. For AML patients, standard therapies often fail to achieve the complete remission, disease relapse is […]
Acute myeloid leukemia (AML) is the most common acute leukemia in adults and a common pediatric cancer. Most often, AML develops from cells that would turn into white blood cells. AML is divided into different subtypes based on the cell type and maturation stage. Currently, monocytic AML, including acute myelomonocytic leukemia (M4) and acute monocytic […]
Hematopoietic stem cells (HSC) accumulate somatic mutations during ageing in healthy individuals . Despite most of these mutations are inconsequential, some HSC can acquire specific mutations providing a competitive advantage leading to a process known as “clonal hematopoiesis of indeterminant potential” (CHIP) . The most common CHIP mutations affects to DNMT3A and TET2 genes and […]
Acute B-cell progenitor acute lymphoblastic leukemia (B-ALL) is a clonal hematopoietic neoplasm characterized by the proliferation and accumulation of B-lymphoid progenitor cells throughout the bone marrow. Although important studies have characterized the underlying biological pathways that underpin therapy failure , resistance and subsequent relapse remain a leading cause of cancer-related deaths . One approach to […]
Acute myeloid leukemia (AML) is the most common type of acute leukemia in adults. This cancer is characterized by the rapid growth of immature myeloid precursors that occupy and alter the bone marrow (BM) niche where normal hematopoietic stems cells (HSCs) reside (the “niche” is the in vivo microenvironment where stem cells reside and receive […]
Acute leukemia is characterized by the proliferation and accumulation of hematopoietic progenitor cells (which are able to differentiate to create specialized cell types) in the bone marrow that impede normal blood production. D epending on the cell population affected, it can be classified in Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML). ALL starts […]
Author: José R. Pineda got his Ph.D. from University of Barcelona in 2006. Since 2007 he has worked for Institut Curie and The French Alternative Energies and Atomic Energy Commission. Currently he is a researcher of the UPV/EHU. He investigates the role of stem cells in physiologic and pathologic conditions. Research in oncology advances very […]